Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Wuxi Biologics (Cayman) ( (HK:2269) ) just unveiled an announcement.
WuXi Biologics (Cayman) Inc. has announced a board meeting scheduled for March 25, 2025, to discuss and approve the annual results for the year ending December 31, 2024. This meeting is significant for evaluating the company’s financial performance and strategizing future operations, impacting its market positioning and stakeholder interests.
More about Wuxi Biologics (Cayman)
WuXi Biologics (Cayman) Inc. operates in the biopharmaceutical industry, providing end-to-end solutions for biologics discovery, development, and manufacturing. The company focuses on accelerating and transforming how biologics are developed and manufactured globally.
YTD Price Performance: 34.72%
Average Trading Volume: 6,070
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $13.74B
Find detailed analytics on 2269 stock on TipRanks’ Stock Analysis page.